Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced the completion of an additional $17.6 million round of financing in an extension of its Series B financing, bringing the total Series B financing raise to $44.7 million. Participating investors in this second Series B round included Forbion Capital Partners, NGN Capital, Arcus Ventures, Tiger Management and CD Ventures.